Abstract
Complete remission from recurrent EBV-positive lymphoma is not mandatory before HSCT to achieve long-term cure in a patient suffering from a recently described immunodeficiency affecting the T-cell coactivation molecule 4-1BB.
Keywords:
4-1BB; Epstein Barr virus; HSCT; Recurrent lymphoproliferation.
Copyright © 2020 Elsevier Inc. All rights reserved.
Publication types
-
Case Reports
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
4-1BB Ligand / deficiency*
-
Child
-
Epstein-Barr Virus Infections / pathology*
-
Epstein-Barr Virus Infections / therapy
-
Hematopoietic Stem Cell Transplantation*
-
Herpesvirus 4, Human / isolation & purification
-
Humans
-
Lymphoma, B-Cell / pathology
-
Lymphoma, B-Cell / therapy*
-
Male
-
Tumor Necrosis Factor Receptor Superfamily, Member 9 / genetics*
Substances
-
4-1BB Ligand
-
TNFRSF9 protein, human
-
Tumor Necrosis Factor Receptor Superfamily, Member 9